Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | RECQL | P46063 | 3/20 | 0.52 |
| ▸ | APEX1 | P27695 | 3/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8402037 | 1.00 | BLM (0.52) | BLMTDP1KDM4EMAPTRECQL | |
| Hydrochloric Acid SCHEMBL4853493 | 0.98 | BLM (0.50) | BLMTDP1KDM4EMAPTRECQL | |
| Hydrochloric Acid SCHEMBL15517746 | 0.84 | BLM (0.50) | BLMTDP1KDM4EMAPTRECQL | |
| Hydrochloric Acid SCHEMBL15511842 | 0.84 | BLM (0.50) | BLMTDP1KDM4EMAPTRECQL | |
| Phenylethanolamine SCHEMBL25831761 | 0.82 | BLM (0.57) | BLMTDP1KDM4EMAPTRECQL | |
| Phenylethanolamine SCHEMBL21723498 | 0.82 | BLM (0.57) | BLMTDP1KDM4EMAPTRECQL | |
| Phenylethanolamine SCHEMBL7150657 | 0.82 | BLM (0.57) | BLMTDP1KDM4EMAPTRECQL | |
| Phenylethanolamine SCHEMBL296410 | 0.82 | BLM (0.57) | BLMTDP1KDM4EMAPTRECQL | |
| SCHEMBL7148580 | 0.82 | BLM (0.57) | BLMTDP1KDM4EMAPTRECQL | |
| SCHEMBL3403672 | 0.82 | BLM (0.57) | BLMTDP1KDM4EMAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109863146-B | Biaryl compounds as immunomodulators | 百时美施贵宝公司 | 2023-02-28 | — | — | CN | disclosed |
| EP-3507284-B1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3507284-A1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2019-07-10 | — | — | EP | disclosed |
| US-10144706-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-04 | — | — | US | disclosed |
| WO-2018044963-A1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20180057455-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-01 | — | — | US | disclosed |
| EP-1423380-B1 | PYRAZOLE-DERIVED KINASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-1423382-B1 | PYRAZOLE-DERIVED KINASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7279476-B2 | Anticancer agents, antiinflamamtory agents, restenosis, cardiovascular disorders; insertable device | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-7183307-B2 | Pyrazole-derived kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCROPORATED (US) | 2007-02-27 | — | — | US | disclosed |
| US-20050215550-A1 | Pyrazole-derived kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2005-09-29 | — | — | US | disclosed |
| US-6875789-B2 | Pyrazole-derived kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040209935-A1 | Pyrazole-derived kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-10-21 | — | — | US | disclosed |
| US-6750239-B2 | USEFUL FOR TREATING DISEASE STATES IN MAMMALS THAT ARE ALLEVIATED BY A PROTEIN KINASE INHIBITOR, PARTICULARLY DISEASES SUCH AS CANCER, INFLAMMATORY DISORDERS, RESTENOSIS, AND CARDIOVASCULAR DISEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-15 | — | — | US | disclosed |
| EP-1423382-A2 | PYRAZOLE-DERIVED KINASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2004-06-02 | — | — | EP | disclosed |
| EP-1423380-A1 | PYRAZOLE-DERIVED KINASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20030144337-A1 | Pyrazole-derived kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-07-31 | — | — | US | disclosed |
| US-20030139452-A1 | Pyrazole-derived kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-07-24 | — | — | US | disclosed |
| WO-2003011855-A2 | PYRAZOLE-DERIVED KINASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003011854-A1 | PYRAZOLE-DERIVED KINASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209935-A1 | Pyrazole-derived kinase inhibitors and uses thereof | RAF1, MAP3K1, MAP3K3 | BLM 1808/4885TDP1 750/4885KDM4E 1767/4885 |
| US-20050215550-A1 | Pyrazole-derived kinase inhibitors and uses thereof | MAP3K19, MAP3K1, MAP3K3 | BLM 1311/4885TDP1 885/4885KDM4E 1942/4885 |
| US-10144706-B2 | Compounds useful as immunomodulators | CD74, HLA-DRB1, CD47 | BLM 549/4885TDP1 2535/4885KDM4E 4249/4885 |
| US-20030139452-A1 | Pyrazole-derived kinase inhibitors and uses thereof | RAF1, MAP3K1, MAP3K3 | BLM 1689/4885TDP1 717/4885KDM4E 1900/4885 |
| US-20180057455-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | CD74, HLA-DRB1, CD47 | BLM 549/4885TDP1 2535/4885KDM4E 4249/4885 |
| US-20030144337-A1 | Pyrazole-derived kinase inhibitors and uses thereof | RAF1, MAP3K1, MAP3K3 | BLM 1808/4885TDP1 750/4885KDM4E 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.